Article Text

Download PDFPDF
PostScript
Clinical characteristics, hospitalisation and mortality rates of COVID-19 among patients with coeliac disease in the USA: a multicentre network study
  1. Emad Mansoor1,
  2. Muhammed Mustafa Alikhan2,
  3. Jaime Abraham Perez3,
  4. Kayla Schlick3,
  5. Mohannad Abou Saleh4,
  6. Alberto Rubio-Tapia4
  1. 1 Department of Medicine; Digestive Health Institute, University Hospitals of Cleveland, Cleveland, Ohio, USA
  2. 2 Department of Medicine, University Hospitals of Cleveland, Cleveland, Ohio, USA
  3. 3 Center for Clinical Research, Case Western Reserve University, Cleveland, Ohio, USA
  4. 4 Department of Medicine; Division of Gastroenterology, Hepatology, and Nutrition, Cleveland Clinic, Cleveland, Ohio, USA
  1. Correspondence to Dr Alberto Rubio-Tapia, Cleveland Clinic, Cleveland, Ohio, USA; rubiota{at}ccf.org

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with interest the work by Belli et al 1 regarding outcomes of COVID-19 in liver transplant candidates. The authors concluded that liver transplant candidates were at risk of early death, especially those with decompensated cirrhosis and model for end-stage liver disease score≥15.

Similarly, patients with coeliac disease (CD) are a population of interest in regards to clinical outcomes after a diagnosis of COVID-19. Although the evidence of an impact of other chronic disorders on the outcome of COVID-19 is emerging, the consequences of COVID-19 infection in individuals with CD remain uncertain.2–4 We sought to define the rates of hospitalisation, mortality, thrombosis or intensive care unit (ICU) requirement in individuals with CD and COVID-19.

We used a large healthcare research network (TriNetX) to compile the electronic medical records of adult patients (age ≥18 years) with CD and confirmed COVID-19 infection (CD cohort) from 51 healthcare organisations in the USA, between 1 January 2020 and 7 July 2021. Within this same time period, we also identified COVID-19 positive patients with no history of CD (non-CD cohort). The definition of …

View Full Text

Footnotes

  • EM and MMA are joint first authors.

  • Twitter @MMAlikhanMD

  • EM and MMA contributed equally.

  • Contributors Study conception and design: EM, MAS and AR-T. Acquisition of data: JAP, KS, EM, MAS and AR-T. Analysis and Interpretation: JAP, KS, MMA, EM, MAS and AR-T. Drafting of manuscript: MMA, EM, MAS and AR-T. Critical revision: MMA, EM, MAS and AR-T. Statistical analysis: JAP, MMA, EM and MAS. Study supervision: EM and AR-T.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.